Nektar Therapeutics (0UNL.L)
USD 1.01
(-1.02%)
USD 1.01
(-1.02%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 210.24 Million USD | 385.89% |
| 2022 | 43.26 Million USD | -63.32% |
| 2021 | 117.95 Million USD | 342.38% |
| 2020 | -48.66 Million USD | -115.82% |
| 2019 | 307.57 Million USD | 490.98% |
| 2018 | 52.04 Million USD | -78.35% |
| 2017 | 240.44 Million USD | 27.25% |
| 2016 | 188.95 Million USD | -1.78% |
| 2015 | 192.37 Million USD | 58.61% |
| 2014 | 121.28 Million USD | 29.05% |
| 2013 | 93.98 Million USD | -15.46% |
| 2012 | 111.17 Million USD | -48.11% |
| 2011 | 214.22 Million USD | 0.01% |
| 2010 | 214.21 Million USD | 16.32% |
| 2009 | 184.15 Million USD | 131.01% |
| 2008 | 79.71 Million USD | -69.65% |
| 2007 | 262.67 Million USD | -29.83% |
| 2006 | 374.36 Million USD | 111.34% |
| 2005 | 177.13 Million USD | 87.15% |
| 2004 | 94.65 Million USD | -71.25% |
| 2003 | 329.25 Million USD | 10.81% |
| 2002 | 297.14 Million USD | -1.3% |
| 2001 | 301.05 Million USD | 63.37% |
| 2000 | 184.27 Million USD | 130.46% |
| 1999 | 79.96 Million USD | 501.57% |
| 1998 | -19.91 Million USD | -103.95% |
| 1997 | -9.76 Million USD | 46.36% |
| 1996 | -18.2 Million USD | -468.75% |
| 1995 | -3.2 Million USD | 67.35% |
| 1994 | -9.8 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 205.68 Million USD | 4.31% |
| 2024 Q1 | 197.19 Million USD | -6.21% |
| 2023 Q2 | 74.02 Million USD | 44.55% |
| 2023 Q3 | 56.36 Million USD | -23.85% |
| 2023 Q4 | 210.24 Million USD | 272.98% |
| 2023 Q1 | 51.2 Million USD | 18.35% |
| 2023 FY | 210.24 Million USD | 385.89% |
| 2022 Q4 | 43.26 Million USD | 49.75% |
| 2022 Q1 | 74.24 Million USD | -37.06% |
| 2022 FY | 43.26 Million USD | -63.32% |
| 2022 Q3 | 28.89 Million USD | -53.33% |
| 2022 Q2 | 61.91 Million USD | -16.6% |
| 2021 Q4 | 117.95 Million USD | 27.6% |
| 2021 FY | 117.95 Million USD | 342.38% |
| 2021 Q1 | 160 Thousand USD | 100.33% |
| 2021 Q2 | -3.91 Million USD | -2544.38% |
| 2021 Q3 | 92.44 Million USD | 2463.62% |
| 2020 Q4 | -48.66 Million USD | -149.39% |
| 2020 Q2 | 98.56 Million USD | -46.73% |
| 2020 Q3 | 98.52 Million USD | -0.04% |
| 2020 Q1 | 185.01 Million USD | -39.85% |
| 2020 FY | -48.66 Million USD | -115.82% |
| 2019 Q4 | 307.57 Million USD | -4.32% |
| 2019 FY | 307.57 Million USD | 490.98% |
| 2019 Q1 | 237.3 Million USD | 355.97% |
| 2019 Q2 | 260.96 Million USD | 9.97% |
| 2019 Q3 | 321.45 Million USD | 23.18% |
| 2018 Q4 | 52.04 Million USD | 114.59% |
| 2018 Q1 | 210.83 Million USD | -12.31% |
| 2018 Q3 | 24.25 Million USD | 103.65% |
| 2018 FY | 52.04 Million USD | -78.35% |
| 2018 Q2 | -665.04 Million USD | -415.43% |
| 2017 Q1 | 224.93 Million USD | 19.04% |
| 2017 FY | 240.44 Million USD | 27.25% |
| 2017 Q4 | 240.44 Million USD | 14.89% |
| 2017 Q3 | 209.28 Million USD | -9.77% |
| 2017 Q2 | 231.94 Million USD | 3.12% |
| 2016 Q3 | 184.22 Million USD | -4.68% |
| 2016 FY | 188.95 Million USD | -1.78% |
| 2016 Q2 | 193.26 Million USD | 8.77% |
| 2016 Q1 | 177.68 Million USD | -7.63% |
| 2016 Q4 | 188.95 Million USD | 2.57% |
| 2015 FY | 192.37 Million USD | 58.61% |
| 2015 Q1 | 5.34 Million USD | -95.59% |
| 2015 Q2 | 112.65 Million USD | 2007.31% |
| 2015 Q3 | 113.39 Million USD | 0.66% |
| 2015 Q4 | 192.37 Million USD | 69.64% |
| 2014 Q3 | 98.33 Million USD | -1.99% |
| 2014 Q2 | 100.32 Million USD | 0.72% |
| 2014 Q1 | 99.6 Million USD | 5.99% |
| 2014 Q4 | 121.28 Million USD | 23.34% |
| 2014 FY | 121.28 Million USD | 29.05% |
| 2013 Q3 | 68.59 Million USD | -26.61% |
| 2013 Q1 | 107.23 Million USD | -3.54% |
| 2013 Q4 | 93.98 Million USD | 37.01% |
| 2013 FY | 93.98 Million USD | -15.46% |
| 2013 Q2 | 93.46 Million USD | -12.84% |
| 2012 Q1 | 80.36 Million USD | -62.49% |
| 2012 FY | 111.17 Million USD | -48.11% |
| 2012 Q4 | 111.17 Million USD | -12.52% |
| 2012 Q3 | 127.07 Million USD | 38.16% |
| 2012 Q2 | 91.97 Million USD | 14.45% |
| 2011 Q1 | 208.91 Million USD | -2.47% |
| 2011 FY | 214.22 Million USD | 0.01% |
| 2011 Q4 | 214.22 Million USD | 14.44% |
| 2011 Q3 | 187.19 Million USD | -14.6% |
| 2011 Q2 | 219.19 Million USD | 4.92% |
| 2010 Q1 | 212.73 Million USD | 15.52% |
| 2010 FY | 214.21 Million USD | 16.32% |
| 2010 Q3 | 219.45 Million USD | 4.7% |
| 2010 Q2 | 209.59 Million USD | -1.47% |
| 2010 Q4 | 214.21 Million USD | -2.39% |
| 2009 Q4 | 184.15 Million USD | -8.56% |
| 2009 Q2 | 119.57 Million USD | 6.16% |
| 2009 FY | 184.15 Million USD | 131.01% |
| 2009 Q1 | 112.64 Million USD | 41.3% |
| 2009 Q3 | 201.4 Million USD | 68.43% |
| 2008 Q1 | 301.91 Million USD | 14.94% |
| 2008 FY | 79.71 Million USD | -69.65% |
| 2008 Q2 | 306.02 Million USD | 1.36% |
| 2008 Q3 | 273.37 Million USD | -10.67% |
| 2008 Q4 | 79.71 Million USD | -70.84% |
| 2007 Q4 | 262.67 Million USD | 14.19% |
| 2007 FY | 262.67 Million USD | -29.83% |
| 2007 Q1 | 318.79 Million USD | -14.84% |
| 2007 Q2 | 318.91 Million USD | 0.04% |
| 2007 Q3 | 230.03 Million USD | -27.87% |
| 2006 FY | 374.36 Million USD | 111.34% |
| 2006 Q1 | 176.27 Million USD | -0.49% |
| 2006 Q4 | 374.36 Million USD | 33.51% |
| 2006 Q3 | 280.4 Million USD | -2.03% |
| 2006 Q2 | 286.2 Million USD | 62.36% |
| 2005 Q4 | 177.13 Million USD | 117.88% |
| 2005 Q1 | 148.78 Million USD | 57.19% |
| 2005 FY | 177.13 Million USD | 87.15% |
| 2005 Q2 | 124.51 Million USD | -16.31% |
| 2005 Q3 | 81.29 Million USD | -34.71% |
| 2004 Q2 | 169.62 Million USD | 401.05% |
| 2004 FY | 94.65 Million USD | -71.25% |
| 2004 Q4 | 94.65 Million USD | -11.52% |
| 2004 Q3 | 106.97 Million USD | -36.93% |
| 2004 Q1 | 33.85 Million USD | -89.72% |
| 2003 Q4 | 329.25 Million USD | -11.87% |
| 2003 Q3 | 373.58 Million USD | 20.27% |
| 2003 Q2 | 310.61 Million USD | 0.14% |
| 2003 Q1 | 310.17 Million USD | 4.39% |
| 2003 FY | 329.25 Million USD | 10.81% |
| 2002 Q4 | 297.14 Million USD | 3.26% |
| 2002 Q2 | 306.22 Million USD | 9.0% |
| 2002 Q1 | 280.94 Million USD | -6.68% |
| 2002 Q3 | 287.77 Million USD | -6.03% |
| 2002 FY | 297.14 Million USD | -1.3% |
| 2001 Q3 | 299.73 Million USD | 190.11% |
| 2001 Q4 | 301.05 Million USD | 0.44% |
| 2001 FY | 301.05 Million USD | 63.37% |
| 2001 Q1 | 238.87 Million USD | 29.63% |
| 2001 Q2 | 103.31 Million USD | -56.75% |
| 2000 Q2 | 153.86 Million USD | 33.95% |
| 2000 Q4 | 184.27 Million USD | 23.23% |
| 2000 Q1 | 114.86 Million USD | 43.66% |
| 2000 Q3 | 149.53 Million USD | -2.81% |
| 2000 FY | 184.27 Million USD | 130.46% |
| 1999 Q2 | -9.75 Million USD | 25.53% |
| 1999 Q3 | -14.38 Million USD | -47.43% |
| 1999 Q4 | 79.96 Million USD | 656.05% |
| 1999 FY | 79.96 Million USD | 501.57% |
| 1999 Q1 | -13.09 Million USD | 34.22% |
| 1998 Q4 | -19.91 Million USD | -49.1% |
| 1998 Q2 | -23.5 Million USD | -272.59% |
| 1998 FY | -19.91 Million USD | -103.95% |
| 1998 Q1 | -6.3 Million USD | 35.38% |
| 1998 Q3 | -13.35 Million USD | 43.19% |
| 1997 Q4 | -9.76 Million USD | -3.0% |
| 1997 Q1 | -36.48 Million USD | -100.48% |
| 1997 FY | -9.76 Million USD | 46.36% |
| 1997 Q2 | -32.98 Million USD | 9.59% |
| 1997 Q3 | -9.47 Million USD | 71.26% |
| 1996 Q3 | -8.4 Million USD | -9.09% |
| 1996 FY | -18.2 Million USD | -468.75% |
| 1996 Q1 | -1.6 Million USD | 50.0% |
| 1996 Q4 | -18.2 Million USD | -116.67% |
| 1996 Q2 | -7.7 Million USD | -381.25% |
| 1995 FY | -3.2 Million USD | 67.35% |
| 1995 Q1 | -19.6 Million USD | -100.0% |
| 1995 Q2 | -6.6 Million USD | 66.33% |
| 1995 Q3 | -2.8 Million USD | 57.58% |
| 1995 Q4 | -3.2 Million USD | -14.29% |
| 1994 FY | -9.8 Million USD | 0.0% |
| 1994 Q3 | -7.6 Million USD | 31.53% |
| 1994 Q4 | -9.8 Million USD | -28.95% |
| 1994 Q1 | -1.4 Million USD | 0.0% |
| 1994 Q2 | -11.1 Million USD | -692.86% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 341.333% |
| Dynavax Technologies Corporation | 106.63 Million USD | -97.159% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 727.077% |
| Perrigo Company plc | 3.32 Billion USD | 93.671% |
| Illumina, Inc. | 1.21 Billion USD | 82.682% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.217% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 284.602% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 97.447% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 98.365% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -44.917% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 875.793% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -2825.282% |
| Waters Corporation | 1.96 Billion USD | 89.276% |
| Biogen Inc. | 6.28 Billion USD | 96.657% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 3061.127% |
| Evolus, Inc. | 63.7 Million USD | -230.006% |
| Adicet Bio, Inc. | -142 Million USD | 248.048% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 2431.854% |
| bluebird bio, Inc. | 108.57 Million USD | -93.643% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 54.166% |
| FibroGen, Inc. | 56.76 Million USD | -270.356% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 81.638% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -2917.189% |
| Homology Medicines, Inc. | 18.43 Million USD | -1040.316% |
| Geron Corporation | 14.76 Million USD | -1324.294% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 86.738% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -6.147% |
| Myriad Genetics, Inc. | 88.1 Million USD | -138.638% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 487.496% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 288.722% |
| Zoetis Inc. | 4.76 Billion USD | 95.585% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 2187.578% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 89.979% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 44.491% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 102.198% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 1542.767% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 80.058% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -559.37% |
| Verastem, Inc. | -37.27 Million USD | 663.979% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 205.214% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 671.242% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 78.289% |
| OPKO Health, Inc. | 230.68 Million USD | 8.862% |
| Exelixis, Inc. | -73.05 Million USD | 387.803% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -18.579% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 255.273% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 239.21% |
| uniQure N.V. | -102.95 Million USD | 304.214% |
| Imunon, Inc. | -4.69 Million USD | 4573.884% |
| Blueprint Medicines Corporation | 702.83 Million USD | 70.087% |
| Insmed Incorporated | 721.62 Million USD | 70.866% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 84.775% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 773.479% |
| TG Therapeutics, Inc. | 17.86 Million USD | -1077.024% |
| Incyte Corporation | -3.17 Billion USD | 106.622% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 72.546% |